Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para evaluar la seguridad y tolerabilidad de GEH200520/GEH200521 (18F) cuando se usa para exploraciones PET en pacientes con tumores malignos sólidos

22 de septiembre de 2026 actualizado por: GE Healthcare

Un estudio de fase 1a/1b, multicéntrico, abierto, de escalada de dosis y de expansión de dosis en pacientes con tumores malignos de tumores sólidos para evaluar la seguridad y tolerabilidad de la inyección de GEH200520 / GEH200521 (18F), imágenes PET, farmacocinética y cambios en Imágenes después del tratamiento

Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.

Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.

Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit. Two late imaging transfer expected post follow up visit. The estimated duration for subject participation in Part B is approximately 64 days.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

19

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Amsterdam, Países Bajos
        • Amsterdam UMC
      • Groningen, Países Bajos
        • UMC Groningen

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
  • The subject is male or female, ≥18 years of age.
  • Subject has a life expectancy ≥12 weeks.
  • Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Subject has an unresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma, or an unresectable stage III-IV melanoma.
  • Subject is eligible for ICI treatment per Investigator judgement.
  • Subject has at least 1 measurable tumour lesion documented on CT/magnetic resonance imaging (MRI) RECIST v1.1 during the last 12 months.
  • Subject has a tumour lesion(s) of which a biopsy can safely be obtained according to standard clinical care procedures.
  • Subject is male or female that agrees to adhere to the protocol contraception methods.

Exclusion Criteria:

  • Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
  • Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
  • Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
  • Subject has serious non-malignant disease or conditions that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has B or T cell lymphoma.
  • Subject has brain or bone-marrow metastasis that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has signs or symptoms of systemic infection within 2 weeks prior to imaging day.
  • Subject has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins or known allergy to the study IMP ingredients and/or the proposed ICI therapy.
  • Subject has any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the ICI treatment, or that may affect the interpretation of the results or render the subject at high risk from complications.
  • Subject has laboratory values out of range per protocol.
  • Subject has any safety laboratory test results (blood chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has had any major surgery within 4 weeks prior to enrollment.
  • Subject has been enrolled in another interventional clinical study within the 30 days before screening for this study, except for the study site IIS.
  • Subject is pregnant or planning to become pregnant or is breastfeeding.
  • Subject has a history of alcohol or drug abuse within the last year.
  • Subject has had treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to dosing with the IMP.
  • Subject has had treatment with systemic immunosuppressive medications within 2 weeks prior to dosing with the IMP.
  • Subject has received acute, low-dose, systemic immunosuppressant medications that, in the opinion of the Investigator, could compromise protocol objectives.
  • Subject has used systemic corticosteroids to treat inflammatory or autoimmune symptoms.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part A Cohort 1 - 1 mg dose

1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 2 - 2 mg dose

2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 3 - 4 mg dose

4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 4 - 8 mg dose

8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 5 (optional) - 12 or 15 mg dose

12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part A Cohort 6 - Optimal dose

Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Experimental: Part B

Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Parte A: La incidencia de los EA sobre la causalidad a los IMP.
Periodo de tiempo: Parte A: 7 días
Parte A: 7 días
Parte A: La gravedad de los EA según los Criterios de Terminología Común para Eventos Adversos del Instituto Nacional del Cáncer (NCI CTCAE versión 5.0) sobre la causalidad de los IMP.
Periodo de tiempo: Parte A: 7 días
Parte A: 7 días
Evaluar los cambios en el transcurso del tiempo en la captación de la inyección de GEH200521 (18F) después de los ciclos de tratamiento con inhibidores del punto de control inmunitario (ICI) en comparación con el valor inicial.
Periodo de tiempo: Parte B: 50 días
Parte B: 50 días

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Evaluar la dosimetría de radiación de una dosis fija de GEH200521 (18F) Inyectable cuando se administra con las diferentes dosis de masa de GEH200520 Inyectable por actividad acumulada en las regiones fuente y por todo el cuerpo.
Periodo de tiempo: 7 días
7 días
Evaluar la ventana de tiempo óptima para la toma de imágenes de tomografía por emisión de positrones (PET) de inyección GEH200521 (18F) cuando se administra con diferentes dosis de masa de inyección GEH200520 para sujetos de la Parte A.
Periodo de tiempo: 7 días
7 días
Determinar la dosis másica adecuada de GEH200520 Inyectable para administrar con GEH200521 (18F) Inyectable para lograr una calidad de imagen PET aceptable para los sujetos de la Parte A.
Periodo de tiempo: 7 días
7 días
Evaluar la inmunogenicidad, a través de la incidencia de respuestas de anticuerpos antidrogas inducidas por el tratamiento, después de una inyección única de las diferentes dosis masivas de GEH200520 Inyectable administradas con una dosis fija de GEH200521 (18F) Inyectable para sujetos de la Parte A.
Periodo de tiempo: 7 días
7 días
Recopilación de la incidencia, gravedad, cambios entre visitas para EA/SAE/AESI
Periodo de tiempo: 50 días
50 días
Evaluar la biodistribución y la captación tumoral de la inyección de GEH200521 (18F) con la dosis de inyección de GEH200520 óptima determinada en la Parte A en función de mediciones cuantitativas de GEH200521 (18F) en regiones de interés para los sujetos de la Parte B.
Periodo de tiempo: 50 días
50 días
Evaluar la relación entre la captación de inyección de GEH200521 (18F) en el tumor (valor SUV) y la puntuación de expresión de CD8+ de células inmunitarias de una muestra de biopsia/lesión resecada cuando esté disponible según los resultados de IHC para sujetos de la Parte B.
Periodo de tiempo: 50 días
50 días
Para comparar los cambios en la captación de la inyección del tumor GEH200521 (18F) con los cambios en la evaluación de imágenes de tomografía computarizada (TC), de acuerdo con los Criterios de evaluación de respuesta en tumores sólidos (RECIST) v1.1 para sujetos de la Parte B cuando esté disponible.
Periodo de tiempo: 50 días
50 días
Para comparar los cambios en la captación de la inyección del tumor GEH200521 (18F) con los cambios en la evaluación de imágenes por tomografía computarizada (TC), según exploraciones con [18F]-fluorodesoxiglucosa (FDG), cuando estén disponibles para los sujetos de la Parte B.
Periodo de tiempo: 50 días
50 días
Para comparar la inmunogenicidad, a través de la incidencia de las respuestas de anticuerpos antidrogas inducidas por el tratamiento, después de múltiples administraciones de GEH200520 Inyectable con GEH200521 (18F) Inyectable para sujetos de la Parte B.
Periodo de tiempo: 50 días
50 días
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Periodo de tiempo: 7 days

The PK parameter to be assessed: AUC

7 days
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Periodo de tiempo: 7 days

The PK parameter to be assessed: Cmax

7 days
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Periodo de tiempo: 7 days

The PK parameter to be assessed: CL

7 days
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Periodo de tiempo: 7 days

The PK parameter to be assessed: V

7 days
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Periodo de tiempo: 7 days

The PK parameter to be assessed: t1/2

7 days
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
Periodo de tiempo: 7 days

Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term

7 days
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Periodo de tiempo: Baseline, 24 hours, 7 days post IMP administration

The findings in the physical exam pre and post-administration will be summarized.

Baseline, 24 hours, 7 days post IMP administration
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Periodo de tiempo: Baseline, 24 hours, 7 days post IMP administration

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, 24 hours, 7 days post IMP administration
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Periodo de tiempo: Baseline, 24 hours, 7 days post IMP administration

Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.

Baseline, 24 hours, 7 days post IMP administration
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Periodo de tiempo: Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration heart rate values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Periodo de tiempo: Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration blood pressure values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Periodo de tiempo: Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration body temperature values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Periodo de tiempo: Baseline, 2 hours, 24 hours, 7 days post IMP administration

Descriptive statistics will be used to describe the observed values and change from baseline.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration physical exam status values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration heart rate values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration blood pressure values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration body temperature values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Periodo de tiempo: Baseline, Day 15, Day 36, Day 50

Descriptive statistics will be used to describe the observed values and change from baseline.

Baseline, Day 15, Day 36, Day 50
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Periodo de tiempo: 50 days

The PK parameter to be assessed: AUC

50 days
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Periodo de tiempo: 50 days

The PK parameter to be assessed: Cmax

50 days
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Periodo de tiempo: 50 days

The PK parameter to be assessed: CL

50 days
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Periodo de tiempo: 50 days

The PK parameter to be assessed: V

50 days
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Periodo de tiempo: 50 days

The PK parameter to be assessed: t1/2

50 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Ravi Karra, MD, GE Healthcare

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de enero de 2023

Finalización primaria (Actual)

4 de agosto de 2026

Finalización del estudio (Actual)

4 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

11 de octubre de 2022

Primero enviado que cumplió con los criterios de control de calidad

17 de noviembre de 2022

Publicado por primera vez (Actual)

29 de noviembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • GE-269-001
  • 2024-515218-42-00 (Ctis)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir